Triple Negative Breast Cancer (TNBC) is one of the most serious cancer. Circular RNA_0001777
(circ_0001777) expression was decreased in TNBC tissues. However, the molecular mechanism
of circ_0001777 remains unknown.
The expression of circ_0001777, microRNA-95-3p (miR-95-3p) and A-kinase anchor protein
12 (AKAP12) were detected by quantitative real-time fluorescence polymerase chain
reaction (qRT-PCR). A series of in vitro experiments were designed to explore the function of circ_0001777 in TNBC cells and
the regulatory mechanism between circ_0001777 and miR-95-3p and AKAP12 in TNBC cells.
Western blot examined the relative protein levels in TNBC cells. Bioinformatics prediction
site predicted the relationship between miR-95-3p and circ_0001777 or AKAP12 and was
verified by Dual-luciferase reporter assays. The xenotransplantation model was established
to study the role of circ_0001777 in vivo.
The expression of circ_0001777 and AKAP12 was decreased in TNBC tissues, while the
expression of miR-95-3p was increased. Circ_0001777 can sponge miR-95-3p, and AKAP12
is the target of miR-95-3p. In vitro complement experiments, overexpression of circ_0001777 significantly decreased the
malignant behavior of TNBC, while co-transfection of miR-95-3p partially up-regulated
this change. In addition, AKAP12 knockdown increased the proliferation, migration,
and invasion of TNBC cells inhibited by overexpression of circ_0001777. Mechanically,
circ_0001777 regulates AKAP12 expression in TNBC cells by sponge miR-95-3p. In addition,
in vivo studies have shown that overexpression of circ_0001777 inhibits tumor growth.
Overexpression of circ_0001777 decreased proliferation, migration, and invasion of
TNBC cells by regulating the miR-95-3p/AKAP12 axis, suggesting that circ_0001777/miR-95-3p/AKAP12
axis may be a potential regulatory mechanism for the treatment of TNBC
Micro Abstract: We found that circ_0001777 positively regulates AKAP12 through sponge
miR-95-3p, thereby inhibiting TNBC progression. These findings provide new targets
for follow-up research and treatment of TNBC.